A 'triple combination' of vitamin C and two standard antibiotics — doxycycline and azithromycin — was sufficient to reduce stem cell growth by more than 90% in laboratory tests.
Finnish researchers have developed a customised DNA nanostructure that can perform a predefined task in human body-like conditions.
Researchers have used genetic engineering to turn a fungus into a natural antibiotic — one which could serve as a promising cure for a neglected tropical disease.
Kazia Therapeutics has summarised data from Part A of its ongoing phase I study of Cantrixil in ovarian cancer — a study which has so far seen promising results.
Australian scientists have conducted what is claimed to be the first ever screening of potential heart regeneration drugs using bioengineered human heart muscle.
Anti-TB drugs cause changes to gut microbiota, increasing susceptibility to Mycobacterium tuberculosis infection as a result.
US scientists have announced promising results from their recent trial of an experimental male oral contraceptive.
Encasing implantable cardiac devices such as pacemakers in a mesh sleeve embedded with antibiotics reduces the risk of major infection by 40%.
For many pharmaceutical manufacturing processes, often very old equipment or technology is still being used.
Koligo Therapeutics, a regenerative medicine and 3D bioprinting company, will list on the Australian Securities Exchange at the end of March via an initial public offering.
UK researchers are working to develop drugs that could be given in the first few hours following a heart attack to minimise heart muscle death caused by the stress signals.
Researchers have discovered a potential new pharmaceutical candidate for tuberculosis, finding that the antimicrobial peptide NZX rapidly and effectively kills TB bacteria.
Scientists have developed a nutrient-rich liquid that enables collected horse semen to live for two weeks outside the body without the need to be frozen.
Trial data showed that Melbourne biotech company Aravax's therapy has a highly favourable safety profile, even in patients with severe peanut allergies.
Direct-acting antivirals have been found to be associated with a reduced risk of liver cancer and death in people with chronic hepatitis C.